Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2015-07-02 Capital/Financing Update
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
Vita 34 Strengthens Market Position via Investments
Capital/Financing Update Classification · 95% confidence The document is a short news release dated July 2, 2015, detailing Vita 34 AG's acquisition of majority stakes in two cooperative partners (Bio Save d.o.o. and Kamieninių ląstelių bankas UAB). It discusses financing, expected revenue contributions, and strategic goals. This type of announcement, concerning corporate transactions like acquisitions and financing activities, aligns best with the 'Capital/Financing Update' category (CAP). Although it is a news release, the core subject matter is a significant capital/financing event (acquisition of voting majority/business interest), making CAP more specific than the general 'RPA' or 'RNS' fallback. The length (4351 chars) is moderate, but the content is a direct announcement of a transaction, not just an announcement *about* a report.
2015-07-02 English
Vita 34 AG: Vita 34 AG acquired 30 percent of company shares of the cooperation partner Bio Save (Serbia)
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as an "Ad-hoc" announcement disseminated according to § 15 WpHG (German Securities Trading Act). The content details a specific corporate action: the acquisition of a 30% stake in a cooperation partner (Bio Save). This type of material event disclosure, which is not a standard periodic report (like 10-K or IR) or a routine announcement (like DIV or DIRS), falls best under the general category for significant, non-standard regulatory disclosures. Since there is no specific code for 'M&A Activity' that covers minority stake acquisitions, and it is a mandatory regulatory disclosure, the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (2545 chars), but it contains the full substance of the announcement, not just a notice that a report is attached.
2015-07-01 English
Vita 34 AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.07.2015 in Leipzig mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is explicitly titled 'Einladung zur ordentlichen Hauptversammlung' (Invitation to the Annual General Meeting) and details the agenda ('Tagesordnung') for a meeting scheduled for July 28, 2015. The agenda items include the presentation of the annual financial statements, proposals for dividend distribution, voting on the discharge of the Management Board and Supervisory Board, election of auditors, and proposed changes to the Articles of Association concerning the Supervisory Board structure and remuneration. These are all core components of an Annual General Meeting notice. Since the document is the formal invitation and agenda for the AGM, the appropriate classification is AGM Information (AGM-R).
2015-06-16 German
Datum:11.06.2015
Board/Management Information Classification · 100% confidence The document is a 'Bericht des Aufsichtsrats' (Supervisory Board Report) for the fiscal year 2014 for Vita 34 AG. This report details the board's activities, corporate governance, and the review of the annual financial statements. In German corporate reporting, the Supervisory Board Report is a mandatory component of the annual reporting package (Geschäftsbericht). Since it is a standalone section of the annual report and not the full 10-K itself, and it focuses on governance and oversight, it falls under the Governance Information category.
2015-06-11 German
Vita 34 Further Expands R&D Activities and Gains Important Insights in Stem Cell Research
Regulatory Filings Classification · 95% confidence The document is a short news release dated June 8, 2015, detailing Vita 34 AG's expansion of R&D activities in stem cell research, including milestones reached and future plans (e.g., cryo-preservation of fatty tissue stem cells, plant stem cell research for skin cream). It is not a formal regulatory filing like a 10-K, nor is it a comprehensive Interim Report (IR). It is an announcement of corporate activity and progress, often distributed via news services like DGAP. Since it is a general corporate update that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate news announcements distributed through official channels.
2015-06-08 English
Datum:07.05.2015
Annual Report Classification · 100% confidence The document is a comprehensive financial report for Vita 34 AG for the fiscal year 2014. It includes the balance sheet, profit and loss statement (GuV), and the notes (Anhang), as well as the auditor's report (Bestätigungsvermerk). Since it covers a full fiscal year and contains detailed financial statements, it is classified as an Annual Report (10-K). FY 2014
2015-05-07 German

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.